Loading...
Loading...
ArQule, Inc.
ARQL today announced the commencement of patient dosing
in a Phase 1 clinical trial with ARQ 087, an orally bioavailable, potent
multi-kinase inhibitor with pan-FGFR (fibroblast growth factor receptor)
activity.
The primary objective of the Phase 1 trial with ARQ 087 is determine its
safety, tolerability and recommended Phase 2 dose. Patients with metastatic
solid tumors who are refractory to available therapies or for whom no standard
systemic therapy exists will be enrolled. The number of patients expected to
be enrolled will depend on the number of patient cohorts investigated until
dose-limiting toxicity is reached.
Fibroblast growth factors (FGF) and their receptors (FGFR) play important
roles in cell proliferation, cell differentiation, cell migration, cell
survival, protein synthesis, and angiogenesis. Dysregulation of FGFR signaling
has been implicated in a number of cancers, including squamous non-small cell
lung cancer (NSCLC), small cell lung cancer (SCLC), gastric, liver, breast,
ovarian, endometrial, and bladder carcinomas, fueling significant interest in
FGFRs as targets for therapeutic intervention.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in